This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

7 Apr 2011

Lupin & Salix Expand Rifaximin Pact

Lupin will receive a $10 million up-front payment as well as potential U.S. regulatory milestones for products covered by Lupin patents or jointly held patents.

Lupin Ltd. has granted Salix Pharmaceuticals, Ltd. exclusive worldwide rights (except for India) to use Lupin technology for all rifaximin products for human use. This agreement expands the companies’ collaboration dating back to September 2009.
Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products for the prevention and treatment of gastrointestinal diseases.
Under the expanded agreement Lupin will supply Salix with rifaximin active pharmaceutical ingredient (API) and certain finished rifaximin products.

Related News